Drug Evaluation Committee For pharmaceutical companies that prepare documents for non-specialists to communicate information on clinical trials in an easy-to-understand manner
Data Science Subcommittee
June 2024
In recent years, as information on clinical trials has become more publicly available and patients and the public have more opportunities to directly access this information, issues related to the content of the publicly available information (e.g., difficulty or lack of understanding of the information described) have become apparent. As one response to this issue, we have organized points to keep in mind in order to convey clinical trial information in an easy-to-understand manner to pharmaceutical company personnel who prepare documents read by patients and citizens who are not medical experts. We hope that this report will help realize better health communication between patients/citizens and pharmaceutical companies in the future.
This report is reprinted from the "Guide to Communicating Medical Research in an Easy-to-Understand Way" prepared by the "Project for Communicating Medical Information in an Easy-to-Understand Way". We would like to express our deepest gratitude to the members of the "Project for Transmitting Medical Information in an Easy-to-Understand Format" for their permission to reproduce this document.
Japan Pharmaceutical Manufacturers Association, Committee on Drug Evaluation
Data Science Subcommittee 2023 Task Force 2-3
Deliverables of the Drug Evaluation Committee Return to list of all deliverables